Cite
APA Citation
Ehrhardt, M., Craveiro, R. B., Velz, J., Olschewski, M., Casati, A., Schönberger, S., Pietsch, T., & Dilloo, D. (2018). the FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma. Journal of cellular and molecular medicine, 22(4), 2153–2161. http://access.bl.uk/ark:/81055/vdc_100057940896.0x000011